Oslo, Norway, February 26, 2007 - Algeta ASA, a therapeutics company dedicated to the development of novel anticancer agents based on alpha particle emitting radionuclides, today announced further positive results, including significant survival data, from a Phase II clinical trial of its lead product Alpharadin™ in patients with late-stage hormone-refractory prostate cancer (HRPC). In addition, Alpharadin was well tolerated and demonstrated an overall benign side effect profile.
